EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2),
(the "Company" or "EXM"), an emerging bio-sciences company
specializing in the production of unique cannabinoid formulations,
is pleased to announce its success in securing COVID-19
R&D-focused grant from the European Union and the Portuguese
Government, detailing a landmark event for the Company.
A Consortium led by EXMceuticals Portugal Lda,
operating under the Project name "BioBlockCOVID" and consisting of
EXMceuticals Portugal Lda, Cosmetek Lda, and the Universidade de
Coimbra has been awarded EUR 302.000 by the European Regional
Development Fund and the Portuguese Government to study further and
develop disinfectants to combat SARScoV-2, the virus that causes
COVID-19.
The BioBlockCOVID project aims to create
functional, natural and innovative biocide formulations that will
specifically target and attack the molecules that make up COVID-19.
The research will focus on the virucidal action of naturally
occurring bioactive compounds from the cannabis plant, in addition
to others. The funding award comes from the competitive tender
opened by the European Regional Development Fund, which finances
two Portuguese funds named Programa Operacional Competitividade e
Internacionalização and Programa Operacional Regional de Lisboa, to
support Companies and R&D entities based in Portugal. The grant
aims to create an incentive system for R&D activities and
investment in testing and optimization infrastructure of relevant
products in combating COVID-19. All required efficacy, performance
and toxicity assessments will be tested in a laboratory
environment, all with a view to the planned industrial
upscaling.
Project lead, Susana Santos, Chief Innovation
Officer at EXMceuticals Portugal, commented: "We are very
confident that the concepts outlined in BioBlockCovid will result
in new practical and state of the art solutions to help control the
pandemic. Alongside our partners working in therapies and vaccines,
we intend to contribute with practical solutions to this very
serious global problem. EXM's overall mission is to combine safe,
natural and bioactive materials with advanced and sustainable
technologies to create products with significant health and
wellness benefits."
The Consortium believes that the BioBlockCOVID
project will result in a set of technical and scientific advances,
specifically combatting the propagation of SARScoV2 and similar
viruses. The use of natural materials will increase efficacy and
also reduce the environmental impact of the currently used chemical
compounds not only found in the production process but also their
end usage.
EXMceuticals Portugal CEO, Paulo Martins, noted:
"We are very pleased to reach this landmark recognition for our
activities in Portugal. I'm very confident and excited with this
new project, which is one of several varied R&D and grant
initiatives that we now have in progress. This grant will enable
EXM Portugal to greatly expand the ongoing work of our research
team on the product innovation side. We will also now accelerate
the operations and projects on our existing pilot cannabinoid
refinery, particularly standardizing and optimizing extraction and
refining protocols. In the coming months, this will allow us to
scale up to the full industrial-scale EU-GMP, pharmaceutical-grade
extraction, refining and purification facility in Portugal."
ON BEHALF OF THE BOARD OF DIRECTORS OF
EXMCEUTICALS INC.
Jonathan Summers, Chairman and Chief Executive
OfficerFor further information, contact: Investor Relations Email:
investors@exmceuticals.com
Media Enquiries:Email:
media@exmceuticals.com
FOR MORE UPDATES ON THE
COMPANY
Follow us on Twitter:
https://twitter.com/EXMceuticals Follow us on
LinkedIn:
https://www.linkedin.com/company/exmceuticalsinc/
ABOUT EXMCEUTICALS
EXM's core activities are centred around the
strategic matching of natural bioactive ingredients extracted from
the cannabis plant with the needs of the nutraceutical,
cosmeceutical, and therapeutic industries. EXMceuticals Portugal,
obtained from INFARMED in November 2019, possesses unique
authorization for cannabis importation and research and development
at its specially equipped laboratory in Lisbon, Portugal. EXM's
team comprises highly qualified scientific and management
professionals covering all areas demanded by the cannabis industry
- organic and analytical chemistry, biology, biochemistry,
genetics, compliance, IP, partnerships, and legal and regulatory
issues.
EXM is in the final stages of detailed planning
for an industrial-scale pharmaceutical standard facility in
Portugal which will complement its existing R&D lab and pilot
refinery. An existing property has been secured in Setubal, south
of Lisbon, which requires retro-fitting to EU-GMP / API standards.
Once complete, the facility will contain extraction, purification,
and refining capabilities, as well as a Q&A laboratory. Once
built, we believe the Setubal facility will be the largest
cannabinoids and terpenes extraction, purification, and refining
facility in the European Union.
The refinery will be able to process cannabis
biomass, extracts, and distillates from Portugal, as well as from
international sources where the regulatory import requirements of
INFARMED have been met. EXM has multiple MOU's in place which will
ensure the refinery can be operated to initial capacity from day 1
and then scaled further. This refinery, once licensed, will
distribute medical cannabis ingredients on a B2B basis, to produce
API's and cannabis-based compounds in a reliable, consistent, and
standardized process. EXM targets and maintains the highest
certification standards to meet the needs of the pharmaceutical,
nutraceutical, and cosmetic industries worldwide.
CSE:
EXM| FSE:
A2PAW2
Neither the CSE nor the FSE has approved nor
disapproved of the contents of this news release. Neither the
CSE nor the FSE accepts responsibility for the adequacy or accuracy
of this release.
Certain information contained herein may
constitute "forward-looking information" under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as, "will
be", "expected", "proposes", "intends" or variations of such words
and phrases or statements that certain actions, events or results
"will" occur. Forward-looking statements regarding the Company's
business operations, the extraction of cannabis ingredients and the
exportation of the extracts, the results of testing at our
facilities established for the European market, future laws and
regulations governing the sale of our products in Europe and
elsewhere, and the potential to generate sales, and completion of a
Qualifying Financing, are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of EXM to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements and forward-looking information. EXM will not update any
forward-looking statements or forward-looking information that is
incorporated by reference herein, except as required by applicable
securities laws.
EXMceuticals (CSE:EXM)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
EXMceuticals (CSE:EXM)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024